Patients Maintenance: The underexamined half of the GLP-1 story GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
News Blackstone buys into Pfizer's GLP-1 drug development Blackstone Life Sciences will provide up to $1.5bn in funding to Pfizer for the development of its once-monthly GLP-1 agonist berobenatide.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
